| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
GenSight Biologics S.A (PA: SIGHT)
SIGHT Technical Analysis
5
| As on 9th Jun 2023 SIGHT STOCK Price closed @ 0.76 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 3.21 & Strong Sell for SHORT-TERM with Stoploss of 4.12 we also expect STOCK to react on Following IMPORTANT LEVELS. |
SIGHTSTOCK Price
| Open | 0.78 | Change | Price | % |
| High | 0.78 | 1 Day | -0.02 | -2.56 |
| Low | 0.75 | 1 Week | -0.07 | -8.43 |
| Close | 0.76 | 1 Month | 0.15 | 24.59 |
| Volume | 107233 | 1 Year | -4.80 | -86.33 |
| 52 Week High 5.72 | 52 Week Low 0.51 | ||||
PA France Most Active Stocks
| FTI | 5.91 | -1.66% |
| VIEDS | 0.72 | 4.35% |
| ALDRV | 0.01 | 0.00% |
| AF | 1.73 | 1.76% |
| CGG | 0.69 | -2.82% |
| ALVMG | 0.50 | 0.00% |
| ACA | 10.83 | -0.91% |
| ALJXR | 0.01 | 0.00% |
| CS | 26.52 | -2.00% |
| GLE | 23.32 | 1.92% |
PA France Top Gainers Stocks
PA France Top Losers Stocks
| SIGHT Daily Charts |
SIGHT Intraday Charts |
Whats New @ Bazaartrend |
SIGHT Free Analysis |
|
|
SIGHT Important Levels Intraday
| RESISTANCE | 0.82 |
| RESISTANCE | 0.80 |
| RESISTANCE | 0.79 |
| RESISTANCE | 0.78 |
| SUPPORT | 0.74 |
| SUPPORT | 0.73 |
| SUPPORT | 0.72 |
| SUPPORT | 0.70 |
SIGHT Forecast May 2024
| 4th UP Forecast | 3.98 |
| 3rd UP Forecast | 2.95 |
| 2nd UP Forecast | 2.31 |
| 1st UP Forecast | 1.67 |
| 1st DOWN Forecast | -0.15 |
| 2nd DOWN Forecast | -0.79 |
| 3rd DOWN Forecast | -1.43 |
| 4th DOWN Forecast | -2.46 |
SIGHT Weekly Forecast
| 4th UP Forecast | 1.42 |
| 3rd UP Forecast | 1.21 |
| 2nd UP Forecast | 1.08 |
| 1st UP Forecast | 0.95 |
| 1st DOWN Forecast | 0.57 |
| 2nd DOWN Forecast | 0.44 |
| 3rd DOWN Forecast | 0.31 |
| 4th DOWN Forecast | 0.10 |
SIGHT Forecast2024
| 4th UP Forecast | 11.3 |
| 3rd UP Forecast | 7.92 |
| 2nd UP Forecast | 5.83 |
| 1st UP Forecast | 3.74 |
| 1st DOWN Forecast | -2.22 |
| 2nd DOWN Forecast | -4.31 |
| 3rd DOWN Forecast | -6.4 |
| 4th DOWN Forecast | -9.78 |
GenSight Biologics S.A ( PA France Symbol : SIGHT )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
SIGHT Business Profile
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ, a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase III clinical trial for the treatment of retinitis pigmentosa, as well as in Phase I/II clinical trial to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France. Address: 74, rue du Faubourg Saint-Antoine, Paris, France, 75012
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service